iFluor® 780 succinimidyl ester
Example protocol
PREPARATION OF STOCK SOLUTIONS
Unless otherwise noted, all unused stock solutions should be divided into single-use aliquots and stored at -20 °C after preparation. Avoid repeated freeze-thaw cycles
Mix 100 µL of a reaction buffer (e.g., 1 M sodium carbonate solution or 1 M phosphate buffer with pH ~9.0) with 900 µL of the target protein solution (e.g. antibody, protein concentration >2 mg/mL if possible) to give 1 mL protein labeling stock solution.
Note: The pH of the protein solution (Solution A) should be 8.5 ± 0.5. If the pH of the protein solution is lower than 8.0, adjust the pH to the range of 8.0-9.0 using 1 M sodium bicarbonate solution or 1 M pH 9.0 phosphate buffer.
Note: The protein should be dissolved in 1X phosphate buffered saline (PBS), pH 7.2-7.4. If the protein is dissolved in Tris or glycine buffer, it must be dialyzed against 1X PBS, pH 7.2-7.4, to remove free amines or ammonium salts (such as ammonium sulfate and ammonium acetate) that are widely used for protein precipitation.
Note: Impure antibodies or antibodies stabilized with bovine serum albumin (BSA) or gelatin will not be labeled well. The presence of sodium azide or thimerosal might also interfere with the conjugation reaction. Sodium azide or thimerosal can be removed by dialysis or spin column for optimal labeling results.
Note: The conjugation efficiency is significantly reduced if the protein concentration is less than 2 mg/mL. For optimal labeling efficiency the final protein concentration range of 2-10 mg/mL is recommended.
Add anhydrous DMSO into the vial of iFluor™ 780 SE to make a 10 mM stock solution. Mix well by pipetting or vortex.
Note: Prepare the dye stock solution (Solution B) before starting the conjugation. Use promptly. Extended storage of the dye stock solution may reduce the dye activity. Solution B can be stored in freezer for two weeks when kept from light and moisture. Avoid freeze-thaw cycles.
SAMPLE EXPERIMENTAL PROTOCOL
This labeling protocol was developed for the conjugate of Goat anti-mouse IgG with iFluor™ 780 SE. You might need further optimization for your particular proteins. Each protein requires distinct dye/protein ratio, which also depends on the properties of dyes. Over labeling of a protein could detrimentally affects its binding affinity while the protein conjugates of low dye/protein ratio gives reduced sensitivity.
Use 10:1 molar ratio of Solution B (dye)/Solution A (protein) as the starting point: Add 5 µL of the dye stock solution (Solution B, assuming the dye stock solution is 10 mM) into the vial of the protein solution (95 µL of Solution A) with effective shaking. The concentration of the protein is ~0.05 mM assuming the protein concentration is 10 mg/mL and the molecular weight of the protein is ~200KD.
Note: We recommend to use 10:1 molar ratio of Solution B (dye)/Solution A (protein). If it is too less or too high, determine the optimal dye/protein ratio at 5:1, 15:1 and 20:1 respectively.
- Continue to rotate or shake the reaction mixture at room temperature for 30-60 minutes.
The following protocol is an example of dye-protein conjugate purification by using a Sephadex G-25 column.
- Prepare Sephadex G-25 column according to the manufacture instruction.
- Load the reaction mixture (From "Run conjugation reaction") to the top of the Sephadex G-25 column.
- Add PBS (pH 7.2-7.4) as soon as the sample runs just below the top resin surface.
Add more PBS (pH 7.2-7.4) to the desired sample to complete the column purification. Combine the fractions that contain the desired dye-protein conjugate.
Note: For immediate use, the dye-protein conjugate need be diluted with staining buffer, and aliquoted for multiple uses.
Note: For longer term storage, dye-protein conjugate solution need be concentrated or freeze dried.
Characterize the Desired Dye-Protein conjugate
The Degree of Substitution (DOS) is the most important factor for characterizing dye-labeled protein. Proteins of lower DOS usually have weaker fluorescence intensity, but proteins of higher DOS tend to have reduced fluorescence too. The optimal DOS for most antibodies is recommended between 2 and 10 depending on the properties of dye and protein. For effective labeling, the degree of substitution should be controlled to have 5-8 moles of iFluor® 780 SE to one mole of antibody. The following steps are used to determine the DOS of iFluor® 780 SE-labeled proteins.
Measure Absorption
To measure the absorption spectrum of a dye-protein conjugate, it is recommended to keep the sample concentration in the range of 1-10 µM depending on the extinction coefficient of the dye.
Read OD (absorbance) at 280 nm and dye maximum absorption (ƛmax = 784 nm for iFluor® 780 dyes)
For most spectrophotometers, the sample (from the column fractions) needs to be diluted with de-ionized water so that the OD values are in the range of 0.1 to 0.9. The O.D. (absorbance) at 280 nm is the maximum absorption of protein while 784 nm is the maximum absorption of iFluor® 780 SE. To obtain accurate DOS, make sure that the conjugate is free of the non-conjugated dye.
Calculate DOS
You can calculate DOS using our tool by following this link:
Spectrum
Product family
Name | Excitation (nm) | Emission (nm) | Extinction coefficient (cm -1 M -1) | Quantum yield | Correction Factor (260 nm) | Correction Factor (280 nm) |
iFluor® 350 succinimidyl ester | 345 | 450 | 200001 | 0.951 | 0.83 | 0.23 |
iFluor® 405 succinimidyl ester | 403 | 427 | 370001 | 0.911 | 0.48 | 0.77 |
iFluor® 430 succinimidyl ester | 433 | 498 | 400001 | 0.781 | 0.68 | 0.3 |
iFluor® 440 succinimidyl ester | 434 | 480 | 400001 | 0.671 | 0.352 | 0.229 |
iFluor® 445 succinimidyl ester | 446 | 558 | - | - | - | - |
iFluor® 450 succinimidyl ester | 451 | 502 | 400001 | 0.821 | 0.45 | 0.27 |
iFluor® 460 succinimidyl ester | 468 | 493 | 800001 | ~0.81 | 0.98 | 0.46 |
iFluor® 488 succinimidyl ester | 491 | 516 | 750001 | 0.91 | 0.21 | 0.11 |
iFluor® 500 succinimidyl ester | 501 | 520 | 800001 | - | 0.206 | 0.088 |
Show More (36) |
Citations
Authors: Wu, Wentao and Liu, Yanyun and Peng, Siyuan and Chen, Yangyan and Ye, Weishi and Wang, Wenhao and Wang, Guanlin and Lu, Chao and Wu, Chuanbin and Pan, Xin and others,
Journal: International Journal of Pharmaceutics (2025): 126000
References
Authors: Krishnan, Giri and van den Berg, Nynke S and Nishio, Naoki and Juniper, Georgina and Pei, Jaqueline and Zhou, Quan and Lu, Guolan and Lee, Yu-Jin and Ramos, Kimberly and Iagaru, Andrei H and Baik, Fred M and Colevas, Alexander D and Martin, Brock A and Rosenthal, Eben L
Journal: Theranostics (2021): 7188-7198
Authors: Kapoor, Shrey and Lu, Guolan and van den Berg, Nynke S and Krishnan, Giri and Pei, Jacqueline and Zhou, Quan and Martin, Brock A and Baik, Fred M and Rosenthal, Eben L and Nishio, Naoki
Journal: Molecular imaging and biology (2021): 270-276
Authors: Yang, Jiang and Zhao, Chunhua and Lim, Jacky and Zhao, Lina and Tourneau, Ryan Le and Zhang, Qize and Dobson, Damien and Joshi, Suhasini and Pang, Jiadong and Zhang, Xiaodong and Pal, Suchetan and Andreou, Chrysafis and Zhang, Hanwen and Kircher, Moritz F and Schmitthenner, Hans
Journal: Theranostics (2021): 2534-2549
Authors: Pei, Jacqueline and Juniper, Georgina and van den Berg, Nynke S and Nisho, Naoki and Broadt, Trevor and Welch, Anthony R and Yi, Grace S and Raymundo, Roan C and Chirita, Stefania U and Lu, Guolan and Krishnan, Giri and Lee, Yu-Jin and Kapoor, Shrey and Zhou, Quan and Colevas, A Dimitrios and Lui, Natalie S and Poultsides, George A and Li, Gordon and Zinn, Kurt R and Rosenthal, Eben L
Journal: Molecular imaging and biology (2021): 109-116
Authors: Dijkstra, Bianca M and de Jong, Marion and Stroet, Marcus C M and Andreae, Fritz and Dulfer, Sebastiaan E and Everts, Marieke and Kruijff, Schelto and Nonnekens, Julie and den Dunnen, Wilfred F A and Kruyt, Frank A E and Groen, Rob J M
Journal: Journal of neuro-oncology (2021): 211-222